The global microbial identification market is projected to expand at 13.2% CAGR during the forecast period of 2023 to 2030. The rising prevalence of infectious illnesses and pandemics, technical improvements, food safety concerns, and government activities and funding to detect and control antimicrobial-resistant species are driving market expansion. Since the beginning of time, bacteria, yeasts, and moulds have been important to human survival. Similar to the past, they are tied to medicine, biotechnology, and genetic engineering. Their unique qualities enable the manufacture of food and food-related products, as well as the decomposition of lignocellulosic biomass as a source of second-generation ethanol or biogas, amino acids, antibiotics, hormones, and other medicinal chemicals. This enables food and food-related items. Some genetic and metabolic features of bacteria make them detrimental to industry (food spoilage) and human health.
Microbiological identification delivers fast, reliable findings, which helps implement applicable therapies quickly. In locations with little healthcare infrastructure, identifying microorganisms helps enhance infectious illness management. Around 1,400 microorganisms can cause human disease. Pathogenic bacteria cause 350 million foodborne illnesses. In the U.S. alone, 48 million instances of the foodborne disease result in 128,000 hospitalizations and 3,000 deaths annually. Inadequate water hygiene causes 1.7 million deaths annually, mostly in children. Most of these deaths occur in underdeveloped countries (NCBI). Infectious infections have risen globally throughout the years. Tuberculosis is one of the top 10 causes of death, according to WHO. 1.5 million people died from TB in 2018. Between 2000 and 2018, tuberculosis identification and treatment saved 58 million lives. According to UNAIDS, there were 1.7 million new HIV infections in 2019, 38 million people are living with HIV, and 690,000 died from AIDS-related illnesses. Zika in 2016, Ebola in 2014, H1N1 swine flu in 2009, H5N1 avian flu in 2004, SARS in 2003, and SARS-CoV-2 in 2019–2020 have caused public health concerns. They increase the requirement for diagnostic tools, especially microbe detectors. High prevalence and incidence of infectious diseases and pandemics drive growth in the microbial identification industry.
Browse for report at : https://www.acutemarketreports.com/report/pharma-microbial-identification-market
Recent years have witnessed huge advances in identifying therapeutically relevant microorganisms. Slowly but steadily, the range of organisms that may be identified has grown, leading to more microorganism strains. MS allows for faster identification of isolated organisms in clinical specimens. The WHO reports at least 30 new diseases in the past 20 years. These diseases threaten hundreds of millions of people worldwide. As infectious disease cases rise, it's more vital to identify the specific bacterium responsible. This contributes to market growth. MS, PCR, and TOF MS are used to identify bacteria (TOF-MS). These advanced microbe detection technologies aren't available everywhere. Such technologies should be widely available within the projection period.
Automated microorganism identification devices include cutting-edge features and functionalities, and their prices reflect this. MALDI-TOF-based systems cost between 150,000 and 850,000 US dollars. Identification methods demand expensive labour and consumables. Many new quick tests cost between $100 and $250, which is more than conventional cultural processes. Equipment, media, and labour are prohibitively expensive for some end users. Automated microbiological identification methods cost between $50,000 and $75,000. Pharmaceutical companies need a lot of this equipment; hence their capital costs are high. Academic research labs rarely have the budget to buy such equipment. Maintenance and other indirect charges increase the total cost of ownership of these devices. This makes automated microbial identification approaches harder to employ widely, especially in small organisations.
Complex regulatory regimes that delay licencing of novel microbiological diagnostic tests are also expected to hinder expansion. Despite this, technological advances, bioterrorism surveillance, and increasing economies are expected to drive the Microbial Identification Market. FDA approval of devices and consumables is time-consuming and confusing. The In Vitro Diagnostic Devices Directive (IVDD) 98/79/EC was abolished and replaced by the IVDR in May 2016. The European Council made IVDR mandatory in 2017. In May 2023, IVDR will be regulated. Businesses have five years to comply with new regulations. These regulations are complex and stricter. Market participants will find it difficult to integrate their procedures with the new legislation, which can temporarily delay bringing new products to market in the U.S. and Europe. This will improve the global market for microbial identification. Regulatory approvals and turnaround times could hinder the market growth during the projection period.
Emerging economies offer opportunities Forecast Period
Emerging economies are expected to drive microbiological identification market growth. Asia Pacific, Middle Eastern, and Latin American regions provide undiscovered prospects for microbe identification firms. Several Asian governments are offering financial aid to ensure the market for microbial identification grows. International organisations have launched various initiatives throughout Asia, including:
Mass spectrometry (MS) is a powerful method for gathering extensive information about proteome modifications, which is needed for individualised therapy. MS's heightened sensitivity has led to the discovery of tumour-specific proteoforms. The confluence of proteomic, genomic, and transcriptome data gives rise to proteogenomics, which may help us comprehend tumour growth. Proteogenomics may explain how tumours originate. These recent discoveries support the importance of MS-based clinical proteomics in cancer research and speed up its integration into clinical diagnosis and treatment.
Among the product and service segment instruments subsegment dominated in 2021 and will continue to do so during the forecast period. The need for equipment is being pushed by a number of factors, most of which are technical improvements in microbial identification methods. Rapid and reliable detection of harmful microorganisms isolated from food samples is vital for monitoring food quality and tracking bacterial outbreaks. Automated microbe identification is becoming common in clinical and food microbiology labs. These technologies reduce labour, human error, sample throughput, and test result turnaround times compared to conventional procedures. Bacterial identification systems are expected to grow 14% annually. By 2030, these systems should account for 30% of global revenues.
With respect to market by methods, 55% of 2021 revenue came from the phenotypic sector. They can recognise a wide range of taxonomic categories, identify actively expressed resistance, and tolerate genetic heterogeneity. The extensive use of phenotypic approaches for identifying microorganisms in the healthcare, food and beverage, pharmaceutical, and environmental industries is driving demand for this category.
Diagnostic applications held 33% of the market in 2021. The rising prevalence of acute and chronic infections, food-borne illnesses, and other disorders fuel microbial identification market sales. Pharmaceutical applications are expected to have the highest CAGR. The growth in pharmaceutical businesses to fulfil the rising demand for novel pharmaceuticals would boost the industry's contribution to the global Microbial Identification Market. Infectious diseases will also boost the industry's contribution.
Panels, ID cards, and media dominated the consumables market in 2021. Panels, ID cards, and other media make identifying microorganisms simple and quick, driving market expansion. Mass spectrometry had the largest market share in 2021 because of its high speed, specificity, and application to bacteria, archaea, and fungi. During the projection period, it had the greatest CAGR. MALDI-TOF technology for identifying microbes is also driving the market growth.
North America dominated the microbiological identification market in 2021. Technological advances in microbial identification, rising infectious disease prevalence, food safety concerns, and important players drive the North American market. The U.S. is expected to continue its robust growth during the projected period, maintaining its leading position in North America with an 85% market share in 2021. Since its 1991 launch as a quick, accurate, and cost-effective technology for identifying more than 1,500 microbial species, fatty acids, and PLFAs by GC-FAME analysis, the Sherlock Microbial Identification System (MIS) has gained popularity in the U.S. The CDC and AOAC International have approved the Sherlock MIS for identifying aerobic bacteria and Bacillus anthracis, the anthrax culprit. This is a major driver in the growth of the country's microorganism identification market.
The Asia Pacific will have the fastest growth from 2023 to 2030. China is predicted to increase at a 10% CAGR over the projection period and hold 52% of the Asian market in 2021. Increasing FDA approvals in China, creative technology development tactics, and manufacturer geographical emergence would enhance the market in the country. In 2021, Europe was the second-largest market. Germany is expected to have a 9.5% CAGR in the European microbial identification market over the forecast period. During the projection period, the pharmaceutical industry's focus on research to develop new therapies and vaccines will boost the German market for microbial identification.
Due to the existence of numerous regional and international market players, the market is fragmented. These organisations are using mergers and acquisitions, partnerships, and new products to satisfy client demand and grow their customer base. Thermofisher Scientific, BioMérieux SA, Beckman Coulter Inc., Shimadzu Corporation, and Becton, Dickinson and Company are market leaders. Regional and smaller firms also dominate the market. Market providers are focusing on fast-increasing categories to maximise potential and recover from the epidemic. They're also maintaining their positions in modestly increasing industries.
